Evonik Roehm Gmbh

Evonik Operations Gmbh

Tom Tice

Norbert Windhab

Rosario Lizio

Matthias Germer

Andreas Karau

Kevin Burton

Andrea Engel

Melanie Liefke

Anne Benedikt

Jessica Müller-Albers

Jian-Feng Zhang

Axel Schroder

Jens Daufenbach

Axel Schroeder

Rima Jaber

Susanne Ullrich

Steffen Kistner

Juan Tome-Alcalde

Milin Shah

Harsh Patel

Mohammad Nikoukar

Rafael Gentsch

Axel SCHRÖDER

An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)

A process for preparing a powder, which includes one or more human coagulation factor proteins and a lactic acid polymer, involves mixing and dispersing a lactic acid polymer with a particle size din the range 0.1-2 &#x3bc;m and the one or more human coagulation factor proteins in water. The dispersion is dried, and the resulting dried mass is compressed. The resulting compressed dried mass is comminuted to a powder with a particle size din the range of more than 0.5 and up to 5 &#x3bc;m.

Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer

Growing community of inventors

Indian Springs, AL, United States of America

Tom Tice